All In Biotech

Drug Trial Radar · NCT03756103

Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study

Last checked: Nov 19, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jan 11, 2019

Primary completion

Jun 30, 2020

Study completion Jun 30, 2020

Sponsor

Sponsor type
Industry
Collaborators
R&G Pharma Studies Co.,Ltd.
First posted
Nov 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension patients.

Conditions

  • Hypertension,Essential

Interventions

  • SPH3127 tablet Dose 1Drug

    Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.

  • SPH3127 tablet Dose 2Drug

    Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.

  • SPH3127 tablet Dose 3Drug

    Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.

  • SPH3127 tablet PlaceboDrug

    Oral SPH3127 tablet placebo, once daily for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes From Baseline in Seated Systolic Blood Pressure (SBP) and Seated Diastolic Blood Pressure (DBP) After 8 Weeks of Treatment.Time frame: Baseline to 54-58 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • The Second Xiangya Hospital of Central South University

    Changsha, China

  • Xiangya Hospital Central South University

    Changsha, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Second People's Hospital of Guangdong Province

    Guangdong, China

  • Inner Mongolia Medical University Affiliated Hospital

    Hohhot, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Xuzhou Central Hospital

    Xuzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.